Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2018 1
2019 1
2020 2
2021 2
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Ramos CA, et al. Among authors: lulla pd. J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23. J Clin Oncol. 2020. PMID: 32701411 Free PMC article. Clinical Trial.
Emerging Challenges to Cellular Therapy of Cancer.
Lulla PD, Brenner M. Lulla PD, et al. Cancer J. 2023 Jan-Feb 01;29(1):20-27. doi: 10.1097/PPO.0000000000000637. Cancer J. 2023. PMID: 36693154 Free PMC article. Review.
Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy.
Kapadia CD, Rosas G, Thakkar SG, Wu M, Torrano V, Wang T, Grilley BJ, Heslop HE, Ramos CA, Goodell MA, Lulla PD. Kapadia CD, et al. Among authors: lulla pd. Cytotherapy. 2024 Mar;26(3):261-265. doi: 10.1016/j.jcyt.2023.11.013. Epub 2023 Dec 26. Cytotherapy. 2024. PMID: 38149948 Free article.
Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL.
Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, Lapteva N, Tao W, Wu M, Grilley B, Carrum G, Kamble RT, Hill L, Krance RA, Martinez C, Tewari P, Omer B, Gottschalk S, Heslop HE, Brenner MK, Rooney CM, Vera JF, Leen AM, Lulla PD. Naik S, et al. Among authors: lulla pd. Blood. 2022 Apr 28;139(17):2706-2711. doi: 10.1182/blood.2021014648. Blood. 2022. PMID: 35134127 Free PMC article.
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.
Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Steffin DHM, et al. Among authors: lulla pd. Blood. 2022 Jul 7;140(1):16-24. doi: 10.1182/blood.2022015728. Blood. 2022. PMID: 35325065 Free PMC article.
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
Lulla PD, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, Lulla S, Carrum G, Ramos CA, Kamble R, Hill L, Randhawa J, Gottschalk S, Krance R, Wang T, Wu M, Robertson C, Gee AP, Chung B, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. Lulla PD, et al. Blood. 2021 May 13;137(19):2585-2597. doi: 10.1182/blood.2020009471. Blood. 2021. PMID: 33270816 Free PMC article. Clinical Trial.
13 results